New US tariffs on generic drugs, starting in 2028, are forcing Indian pharmaceutical companies to rethink their business models. Many firms are now moving away from low-margin commodity drugs toward specialty products and biologics. This shift is essential for companies heavily exposed to the US market, where future import costs could severely impact profitability.
The US government has finalized a phased plan to impose tariffs on imported generic medicines. While these drugs will remain duty-free until August 2028, the import tax will rise to 100% in August 2028 and to 200% by August 2029. This policy, designed to encourage drug manufacturing within the United States, marks a turning point for Indian pharmaceutical exporters that have long dominated the US generic market.
When the announcement was made in late July 2026, the Nifty Pharma index declined by nearly 2% as investors assessed the long-term impact on the sector. Companies with high exposure to the US, such as Lupin, Aurobindo Pharma, and Dr. Reddy's Laboratories, saw share price drops as the market reacted to the news. The primary concern is the thin profit margins associated with traditional generic pills, which are highly sensitive to any increase in costs.
Moving production to the United States is not a simple solution for most Indian firms. Building and running manufacturing plants in the US involves significantly higher costs than operating in India. Consequently, industry leaders are focusing on a different strategy. Instead of trying to replicate low-cost generic production in the US, companies are increasing their investments in specialty and high-value medicines. This category includes biologics and complex biosimilars, which often command better profit margins and are less affected by simple volume-based tariffs.
The path forward involves significant execution risks. Many Indian companies still rely on key raw materials sourced from overseas, which complicates the supply chain. Shifting a product mix toward complex drugs requires substantial research and development spending, which can pressure cash flow in the short term. Furthermore, if companies cannot successfully make this transition, they risk losing market share in the United States, which remains a primary revenue driver for the sector.
Investors tracking these companies should watch for changes in product portfolios and profit margin trends. The speed at which firms can reduce their dependence on commodity generics and grow their share of specialty drugs will be a key indicator of long-term business health. Management commentary on US market strategy and research spending will be important to monitor in upcoming quarterly earnings reports.